Scandinavian Real Heart AB (SE:HEART)
:HEART
Want to see SE:HEART full AI Analyst Report?
HEART Stock Chart & Stats
kr25.80
kr0.30(2.04%)
At close: 4:00 PM EST
kr25.80
kr0.30(2.04%)
Day’s Range― - ―
52-Week Rangekr12.65 - kr29.89
Previous CloseN/A
Volume1.18K
Average Volume (3M)7.92K
Market Cap
kr189.50M
Enterprise Valuekr86.66M
Total Cash (Recent Filing)kr27.94M
Total Debt (Recent Filing)kr5.40M
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.57
Shares Outstanding8,497,797
10 Day Avg. Volume3,221
30 Day Avg. Volume7,918
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)1.11
Price to Sales (P/S)0.00
P/FCF Ratio-4.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr42.00M
Bulls Say, Bears Say
Bulls Say
Unique Total Artificial Heart ProductThe company is developing an implantable Total Artificial Heart (Realheart TAH) to treat advanced heart failure. This is a structurally differentiated medical-device opportunity addressing a severe unmet clinical need, offering durable upside if regulatory and clinical milestones are achieved.
Relatively Low Financial LeverageModest debt levels provide lasting financial flexibility versus highly leveraged peers, reducing fixed interest obligations and easing short-term solvency pressure. This structural balance-sheet advantage helps sustain development through regulatory cycles if funding is secured.
Lean, Focused Operating StructureA very small, specialized headcount implies low fixed overhead and focused R&D execution, which can extend runway per unit of cash spent. Structurally, a lean team can enable disciplined spending on clinical and regulatory priorities, though scaling later will require investment.
Bears Say
Effectively Pre-revenueThe company lacks a commercial revenue base, leaving operations fully dependent on financing rather than organic cash generation. Over the medium term this limits reinvestment capacity, amplifies dilution risk, and means value realization depends on successful clinical and regulatory progress.
Consistent Negative Operating And Free Cash FlowSustained operating and free cash-flow deficits indicate ongoing cash burn without self-funding. This structural cash drain necessitates external capital for development and trials, creating recurring financing needs that can dilute shareholders and constrain long-term strategic flexibility.
Declining Equity Base And Negative ReturnsA falling equity base alongside materially negative returns on equity signals value erosion and repeated financing or losses. Structurally, this trend weakens the equity cushion, increases vulnerability to future dilution, and reduces resilience during lengthy regulatory and commercialization timelines.
HEART FAQ
What was Scandinavian Real Heart AB’s price range in the past 12 months?
Scandinavian Real Heart AB lowest stock price was kr12.65 and its highest was kr29.89 in the past 12 months.
What is Scandinavian Real Heart AB’s market cap?
Scandinavian Real Heart AB’s market cap is kr189.50M.
When is Scandinavian Real Heart AB’s upcoming earnings report date?
Scandinavian Real Heart AB’s upcoming earnings report date is Aug 28, 2026 which is in 75 days.
How were Scandinavian Real Heart AB’s earnings last quarter?
Currently, no data Available
Is Scandinavian Real Heart AB overvalued?
According to Wall Street analysts Scandinavian Real Heart AB’s price is currently Overvalued.
Does Scandinavian Real Heart AB pay dividends?
Scandinavian Real Heart AB does not currently pay dividends.
What is Scandinavian Real Heart AB’s EPS estimate?
Scandinavian Real Heart AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Scandinavian Real Heart AB have?
Scandinavian Real Heart AB has 8,497,797 shares outstanding.
What happened to Scandinavian Real Heart AB’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Scandinavian Real Heart AB?
Currently, no hedge funds are holding shares in SE:HEART
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Scandinavian Real Heart AB
Scandinavian Real Heart AB (Publ), a Swedish enterprise established in 2007, specializes in the innovation and production of artificial heart devices. The company's core focus is the Realheart TAH, a total artificial heart engineered specifically to address severe cases of heart failure. Beyond this central project, their product portfolio also encompasses medical solutions such as the RealVAD, PulsePump, and Sternal Prosthesis. The firm operates from its base in Västerås, Sweden.